Research status and progress on respiratory syncytial virus vaccines
10.13200/j.cnki.cjb.004597
- VernacularTitle:呼吸道合胞病毒疫苗的研究现状及进展
- Author:
Chenglong LI
- Publication Type:Journal Article
- Keywords:
Respiratory syncytial virus(RSV);
Subunit vaccines;
mRNA vaccines;
Live attenuated vaccines;
Viral vector vaccines;
Clinical trials
- From:
Chinese Journal of Biologicals
2025;38(11):1393-1400+1407
- CountryChina
- Language:Chinese
-
Abstract:
Respiratory syncytial virus(RSV), an RNA virus, is one of the leading pathogens causing respiratory tract infections in infants, the elderly and immunocompromised people, resulting in a huge medical burden of disease worldwide every year. The fusion protein(F protein) on the surface of RSV is the main target of neutralizing antibodies, especially the discovery of its pre-fusion conformation(pre-F), which has laid a key theoretical foundation for the design of a new generation of vaccines. In view of the current limited effective prevention and treatment methods for RSV-related diseases, it is necessary to develop effective vaccines, and vaccines of various technical routes, including subunit vaccines, mRNA vaccines,live attenuated vaccines and viral vector vaccines, are under the development stage. Among them, some RSV vaccine prouducts for the elderly and pregnant women have been approved for marketing. This paper mainly outlines the problems encountered in the early development of RSV vaccines, the current status and progress of RSV vaccine research, in order to provide reference for the follow-up development, clinical evaluation and immunization strategy formulation of RSV vaccines.
